MediPharm Labs Addresses Misinformation from Shareholder Dispute

MediPharm Labs Responds to Misinformation from Shareholder

TORONTO – MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ), a leader in pharmaceutical-grade cannabinoid products, has stepped forward to address recent misleading claims made by Apollo Technology Capital Corporation. It appears Apollo has orchestrated a smear campaign filled with fabricated allegations aimed at distracting shareholders and seizing control over MediPharm’s Board of Directors.

Setting the Record Straight

The claims put forth by Apollo lack any basis in truth. MediPharm Labs maintains a strong commitment to transparency and integrity, evidenced by its recent completion of a thorough year-end audit conducted by MNP LLP. The results were favorable, with a clean audit opinion dated March 30, a tradition the company has upheld since its public listing. Unlike quarterly reports, which do not require audits by public companies, MediPharm adheres to all financial standards and obligations under Canadian securities law.

Legal Action Initiated

In light of these detrimental accusations, MediPharm has initiated legal proceedings to address the material misrepresentations propagated by Apollo. The company is confident in its stance and is pursuing court action to rectify the misinformation, seeking to have the associated litigation costs awarded.

About MediPharm Labs

MediPharm Labs has made significant strides in the cannabinoid industry since its inception in 2015. The company is recognized for its meticulous approach to developing and manufacturing purified, pharmaceutical-quality cannabis concentrates and advanced derivative products. Utilizing a Good Manufacturing Practices certified facility along with state-of-the-art technology, MediPharm is committed to crafting high-quality products that provide safe and effective cannabinoid solutions to medical patients.

Significant Achievements

In 2021, MediPharm made history by obtaining a Pharmaceutical Drug Establishment License from Health Canada, becoming the first company in North America to hold a commercial-scale domestic GMP License for the extraction of natural cannabinoids. This pioneering step is part of the company’s ongoing efforts to establish a foreign drug manufacturing site registered with the US FDA.

Expanding Global Reach

The acquisition of VIVO Cannabis Inc. in 2023 marked a major expansion for MediPharm Labs, broadening access to medical patients in Canada and establishing a presence in Australia and Germany through its affiliates. The acquisition has also integrated Harvest Medical Clinics, which offers expert consultations and education for medical cannabis patients.

Shareholder Support and Communication

MediPharm believes in maintaining open lines of communication with its shareholders. Should any concerns arise regarding proxy forms or voting instruction, shareholders are encouraged to reach out to Sodali & Co. for assistance. Their dedicated team is available to ensure shareholders are fully supported through the voting process.

Contact details are as follows:

• North American Toll-Free Number: 1.888.777.2059
• Outside North America: 1.289.695.3075
• Email: assistance@investor.sodali.com
• Fax: 1.877.218.5372

Investor and Media Contacts

For any investment inquiries, please contact:

MediPharm Labs Investor Relations
Telephone: +1 416.913.7425
Email: investors@medipharmlabs.com

For media inquiries, please contact John Vincic at Oakstrom Advisors: +1 (647) 402-6375 or at john@oakstrom.com

Frequently Asked Questions

What allegations is MediPharm Labs addressing?

MediPharm Labs is responding to false claims made by Apollo Technology Capital regarding the company's management practices.

Why is MediPharm taking legal action?

The company is pursuing legal action to counter material misstatements made by Apollo and to recover litigation costs.

What regulatory compliance does MediPharm have?

MediPharm complies with International Financial Reporting Standards and Canadian securities law requirements.

What is MediPharm's main area of expertise?

The company specializes in creating pharmaceutical-grade cannabis concentrates and advanced cannabinoid-based products.

How can shareholders get assistance regarding voting?

Shareholders can contact Sodali & Co. for any inquiries related to proxy forms or voting assistance.

About The Author

My name is Dylan Bailey, and I am 28 years old. I am an author and an expert on the stock market who specializes in publicly traded companies. Early fascination with the stock market inspired me to seek a finance degree and then delve deeply into the world of stocks. I have developed over the years my abilities to spot investment prospects, assess business performance, and analyze market trends.

My books and articles try to help regular investors understand the nuances of the stock market. Anyone can, in my opinion, make wise investment choices and succeed financially if they have the correct information and resources. In my writing, I combine in-depth research with practical insights and advice that can be put into action. This is done with the intention of assisting readers in navigating the constantly shifting landscape of publicly traded companies.

In addition to writing, I also host webinars and workshops, where I give presentations and share my knowledge with a wider audience. I also write for top financial journals and show up as a guest analyst on financial news shows. I like to travel, spend time with my family, and keep active by playing different sports when I'm not buried in market research.

My goal is to enable people to choose wisely and consciously in their investments, so taking charge of their financial futures. By my work, I hope to create a community of informed and self-assured investors prepared to take advantage of the chances presented by the stock market.

Contact Dylan Bailey privately here. Or send an email with ATTN: Dylan Bailey as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.